Abstract: Objective To evaluate the efficacy and adverse reaction of cetuximab combined with FOLFOX 4 regimen as neoadjuvant therapy for colorectal cancer with liver metastases. Methods A total of 18 patients with liver metastases from colorectal cancer were treated with cetuximab combined with FOLFOX 4 regimen. Cetuximab 400mg／m2 was intravenously given at the first dose and maintenance at 250mg／m2 every week for a total of 6 weeks. FOLFOX 4 regimen was given as follows： oxaliplatin 85mg／m2 iv，d1；calcium folinate 200mg／m2 iv，d1，d2； fluorouracil 400mg／m2 bolus，d1，d2，and then 600mg／m2 civ for 22h，d1，d2，2 weeks was a cycle. The efficacy were evaluated after 3 cycles.
ResultsThe efficacy could be evaluated in eighteen patients，with PR in 15 cases，SD in 2 cases，and PD in 1 case. The response rate was 83.3％ and the disease control rate was 944％. Eighteen patients received surgery, 14 of them underwent synchronous radical colorectal surgery and liver metastases resection, and 4 cases received stage operation. R0 resection of primary lesion was performed in 18 patients, while R0 resection of liver metastases was operated in 15 cases and R1 resection in 3 cases. The median overall survival was 30.4 months, and the median progressionfree survival was 21.2 months. The adverse reaction during the treatment included grade 3 skin toxicity, grade 1-2 delayed diarrhea and grade 1-2 neutropenia. Conclusion FOLFOX 4 regimen combined with cituximab neoadjuvant therapy for colorectal cancer with liver metastases is effective and well-tolarable，which can increase the resectabiliy rate and prolong patients'survival may provide a new treating strategy for colorectal cancer with liver metastases.